Amgen Girds For Competition In High-Stakes RA Therapy Field
A longstanding squabble between Amgen Inc. and Johnson & Johnson over epoetin alfa ended last week with an arbitrator's $150 million decision favoring the former, just as another skirmish - not legal - began to heat up between the pair. (BioWorld Financial Watch)
